• 1
    Guillonneau B, El-Fettouh H, Baumert H et al. Laparoscopic radical prostatectomy: oncological evaluation after 1000 cases at montsouris institute. J Urol 2003; 169: 12611266
  • 2
    Goeman L, Salomon L, De La Taille A et al. Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World J Urol 2006; 24: 281288
  • 3
    Rassweiler J, Sentker L, Seemann O, Hatzinger M, Stock C, Frede T. Heilbronn laparoscopic radical prostatectomy: technique and results after 100 cases. Eur Urol 2001; 40: 5464
  • 4
    Menon M, Bhandari M, Gupta N et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 2010; 58: 838846
  • 5
    Heidenreich A, Bolla M, Joniau S et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2010; 28: S18737560 [Epub ahead of print].
  • 6
    Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 21062131
  • 7
    Ficarra V, Novara G, Artibani W et al. Retropubic, laparoscopic and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009; 55: 10371063
  • 8
    Salomon L, Levrel O, Taille A et al. Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. Eur Urol 2002; 42: 104111
  • 9
    Secin FP, Bianco FJ, Karanikolas NT, Touijer K, Guillonneau B. Oncologic outcomes of laparoscopic radical prostatectomy: intermediate-term follow-up. Eur Urol 2006; 5 (Suppl.): 934941
  • 10
    Touijer K, Secin FP, Cronin AM et al. Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol 2009; 55: 10141019
  • 11
    Walz J, Chun FK-H, Klein EA et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009; 181: 601608
  • 12
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. Urol Clin North Am 2001; 28: 555565
  • 13
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910914
  • 14
    Budäus L, Isbarn H, Schlomm T et al. Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 2009; 56: 317324
  • 15
    Krygiel JM, Smith DS, Homan SM et al. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer. J Urol 2005; 174: 126130
  • 16
    Kestin JJ, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999; 86: 15571566
  • 17
    Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; (4): CD006019
  • 18
    Xylinas E, Drouin SJ, Comperat E et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int 2009; 103: 11731178
  • 19
    Siddiqui SA, Boorjian SA, Blute ML et al. Impact of adjuvant andogen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 2011; 107: 383388
  • 20
    Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766771
  • 21
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 14991507
  • 22
    Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 18211825
  • 23
    Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 18501857
  • 24
    Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol 1998; 55: 904908
  • 25
    Hull GW, Rabbani F, Abbas F. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528534
  • 26
    Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004; 172: 13281332
  • 27
    Palisaar RJ, Noldus J, Graefen M, Erbersdobler A, Haese A, Huland H. Influence of nerve-sparing procedure during radical prostatectomy on margin status and biochemical failure. Eur Urol 2005; 47: 176184
  • 28
    Carver BS, Bianco FJ, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stageT3 prostate cancer. J Urol 2006; 176: 564568
  • 29
    Chun FKH, Graefen M, Zacharias M et al. Anatomic radical retropubic prostatectomy – long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006; 24: 273280
  • 30
    Carini M, Masieri L, Minervini A, Lapini A, Serni S. Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. Eur Urol 2008; 53: 554563